People channel feed

What makes Hal Bar­ron tick? Look at the peo­ple he’s team­ing up with at GSK

6 years ago
Bioregnum
Opinion

FDA’s Wood­cock weighs in on role of NIH in drug de­vel­op­ment

6 years ago
FDA+

No­var­tis, As­traZeneca vet Jonathan Symonds steers back to a top post in Big Phar­ma, this time at GSK

6 years ago
R&D

Break­ing the death spi­ral: Hal Bar­ron talks about trans­form­ing the mori­bund R&D cul­ture at GSK in a crit­i­cal year for the late-stage pipeline

6 years ago
R&D

Af­ter a decade, Vi­iV CSO John Pot­tage says it's time to step down — and he's hand­ing the job to long­time col­league Kim Smith

6 years ago
R&D

Biotech uni­corns first to go as Neil Wood­ford auc­tions as­sets off sus­pend­ed fund — re­port

6 years ago
Financing

The $1.1M good­bye: Gilead CSO John McHutchi­son is out as Daniel O’Day shakes up the se­nior team

6 years ago

In­ovio ax­es staff, chops R&D pro­grams in chase for elu­sive com­mer­cial win — though there's still a lot on their plate

6 years ago

Part club, part guide, part land­lord: Arie Bellde­grun is blue­print­ing a string of be­spoke biotech com­plex­es in glob­al boom­towns — start­ing with Boston

6 years ago
Financing

Takeda's trans­la­tion­al cell ther­a­py group revs up for a race to the clin­ic with off-the-shelf CAR-T

6 years ago
Cell/Gene Tx

GSK to tap Jonathan Symonds as chair­man, lever­ag­ing Big Phar­ma ex­pe­ri­ence for con­sumer biz deal

6 years ago

Fresh out of Eli Lil­ly, Christi Shaw sur­faces as Daniel O'­Day's new CEO at CAR-T pi­o­neer Kite

6 years ago
Cell/Gene Tx

Eli Lil­ly's Christi Shaw bows out of top post at the Bio-Med­i­cines unit

6 years ago

No clear an­swers: Yes, re­cent ac­tions against Chi­nese Amer­i­can sci­en­tists do pose a threat — but maybe those of­fi­cial con­cerns about es­pi­onage are valid too

6 years ago
China

Al­ny­lam’s Maraganore switch­es ‘per­haps the best CFO in mid-cap biotech’ with Shire vet Jeff Poul­ton

6 years ago

Glax­o­SmithK­line re­cruits a new coach and top play­er for their AI/ML team out of Genen­tech and MIT

6 years ago
AI

As­tex vet Neil Thomp­son looks to build dis­cov­ery from scratch at rare dis­ease AI up­start out of Cam­bridge, UK

6 years ago
AI

The FDA's Janet Wood­cock talks about some big changes she's push­ing for in drug de­vel­op­ment, and agency re­views

6 years ago
FDA+

Fresh out of be­lea­guered Mer­ri­mack, Richard Pe­ters jumps in­to the wel­come arms of Tony Coles at Yu­man­i­ty

6 years ago

Ex-Genen­tech star and 23andMe vet Richard Scheller jumps to new­ly pub­lic uni­corn biotech Bridge­Bio as ‘chair­man of R&D’

6 years ago

Elias Zer­houni: Fear of ‘tar­get­ed dis­crim­i­na­tion’ against Chi­nese-Amer­i­can sci­en­tists threat­ens an ex­o­dus of tal­ent. What do you think?

6 years ago
China

Pledg­ing a come­back, Ac­er ax­es pre-com­mer­cial ops, chops staffers in wake of CRL

6 years ago

The chief sci­en­tist at Ger­man/US biotech hy­brid Im­mat­ics is mov­ing to the helm. Here's his to-do list

6 years ago
R&D
Cell/Gene Tx

Go­ing for it: GSK’s Hal Bar­ron out­lines a big PhI­II pro­gram for rheuma­toid arthri­tis — go­ing head-to-head with gi­ant ri­vals

6 years ago
R&D
First page Previous page 76777879808182 Next page Last page
A service from the Financial Times